FBXO2 promotes hepatocellular carcinoma progression and sorafenib resistance by targeting USP49 for proteasomal degradation
Collectively, our findings establish FBXO2 as a critical modulator of HCC progression and therapeutic resistance via USP49 degradation, highlighting FBXO2 as a promising therapeutic target for overcoming sorafenib resistance in HCC.
Authors
- Dong Yiwei (ORCID: https://orcid.org/0000-0002-6162-9617)
- Qingqing Wang (ORCID: https://orcid.org/0000-0001-8378-1057)
- Bo Hu (ORCID: https://orcid.org/0000-0003-0976-9070)
- Peter Wang (ORCID: https://orcid.org/0000-0003-1997-9653)
- Xu Liu
- Sirui Hang
- Jie Zhang (ORCID: https://orcid.org/0009-0004-5173-9996)
Institutions
- Zhejiang Chinese Medical University (CN)
- Northeastern University (US)
- Beijing Emergency Medical Center (CN)
- First Hospital of Jiaxing (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3389/fimmu.2025.1660034
- Citations
- 3
- Primary Topic
- Ubiquitin and proteasome pathways
- Type
- article
- Field-Weighted Citation Impact
- 2.42
Funders
- Natural Science Foundation of Zhejiang Province